Withings

Antoine Robiliard, VP of health solutions at Withings, told MobiHealthNews that 2025 is set to bring growth in at-home care, M&A-driven scalability and a clearer understanding of AI's practical impact on healthcare.

The aim is to deliver clinical insights and improve patient engagement.   

U-Scan, an in-home biomarker analysis platform, sits within the toilet bowl to analyze the user's urine.

The UK-based wearable medical device company plans to use the funds to expand in Europe and North America.

The partnership will allow Withings' connected scales, blood pressure monitors and sleep-tracking mats to integrate with Medable's trial platform.

Withings announced its B2B division, which included its first remote patient monitoring offering, in 2019.

Also: the Surgeon General asks big tech for COVID-19 misinformation data, and Eden Health launches a personal care offering. 

The acquisition comes just after the health tech company announced it had purchased device maker Impeto Medical.

Impeto’s SUDOSCAN technology for monitoring peripheral neuropathies is included in Withings’ recently announced Body Scan smart scale.

The company said the smart scale will be available in the latter half of 2022 following regulatory clearance.